Back

Modeling adaptive therapy in non-muscle invasive bladder cancer

Ferrall-Fairbanks, M. C.; Kimmel, G. J.; Black, M.; Bravo, R.; Deac, O.; Martinez, P.; Myers, M.; Nazari, F.; Osojnik, A.; Subramanian, H.; Viossat, Y.; Whiting, F.; Li, R.; Mann, K. M.; Altrock, P. M.

2019-11-06 cancer biology
10.1101/826438 bioRxiv
Show abstract

Bladder cancer is the 9th most commonly diagnosed cancer. Nearly half of patients with early stage bladder cancer treated with the immune-stimulating agent BCG have disease recurrence, while 13% progress to invasive bladder cancer. Here we explored the potential of tumor mutational heterogeneity and the role of pro- and anti-inflammatory cytokines to identify different subtypes of bladder cancer that may predict therapeutic response to BCG. Further, we used mathematical modeling of dosing strategies to infer tumor response to varying doses and time schedules f BCG administration. As a proof-of-concept, present adaptive therapy scheduling of BCG as a viable strategy to control tumor size and minimize recurrence.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.